Joseph Fernandes, MD
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,300 of the $7,592 with a category attached, or 83.0%. Biogen accounts for 96.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $7,338 and has fallen 97.8% since, to $162 in 2025.
Across 14 payments — averaging $542.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$7K
- UCB, Inc.$162
- Argenx US, Inc.$93
Across 35 payments — averaging $9697.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$178K
- PTC Therapeutics, Inc.$71K
- Mallinckrodt Enterprises LLC$38K
- Biohaven Pharmaceutical Holding Company Ltd.$21K
- Mallinckrodt Hospital Products Inc.$19K
- UCB SA$13K
What the payments were for
- Consulting fees$6,30083%
- Travel & lodging$3655%
- Food & beverage$92812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 12 | $7,338 |
| UCB, Inc. | 1 | $162 |
| Argenx US, Inc. | 1 | $93 |
How this compares
$7,592 in reported general payments places this provider in the 80th percentile of 105 neurology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 79 | $1,132,593 |
| EvrysdiRisdiplam | 15 | $394,236 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 13 | $170,204 |
| NuedextaDextromethorphan Hbr/Quinidine | 36 | $66,218 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $35,755 |
| Riluzole | 62 | $11,511 |
| Pyridostigmine Bromide | 35 | $3,609 |
| Azathioprine | 20 | $1,825 |
| Mycophenolate Mofetil | 31 | $1,755 |
| Scopolamine | 13 | $1,018 |
| Glycopyrrolate | 24 | $838 |
| Cyclosporine ModifiedCyclosporine, Modified | 17 | $838 |
| Gabapentin | 68 | $757 |
| Baclofen | 29 | $582 |
| Duloxetine Hcl | 30 | $532 |
Paid to pharmacies, not to this prescriber.
Other neurology in Omaha
- Chad WhyteOmaha$647K
- Scott GoodmanOmaha$377K
- Rana ZabadOmaha$276K
- Deepak MadhavanOmaha$189K
- Pamela SantamariaOmaha$90K
- Peter SohOmaha$60K
- Kiel WoodwardOmaha$32K
- Pierre FayadOmaha$24K
- Jonathan MoravekOmaha$19K
- Erin SmithOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.